Hyperthermic Intraperitoneal Chemotherapy plus Intravenous Chemotherapy of Paclitaxel with or without Sintilimab in Gastric Cancer: A Comparative Study

Table 4

Comparison of long-term outcome.

	PFS (%)		OS (%)
	6 month	12 month	6 month	12 month
Control group (n = 60)	46	16	51	34
Study group (n = 60)	50	27	55	48
χ^2	1.768	4.385	1.294	7.548
value	0.184	0.036	0.255	0.006

PFS, progression-free survival; OS, overall survival.